Old Web
English
Sign In
Acemap
>
authorDetail
>
Lei Shu
Lei Shu
Astellas Pharma
Refractory
Oncology
Myeloid leukemia
Pathology
Chemotherapy
3
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
2017
Journal of Clinical Oncology
Alexander E. Perl
Jorge E. Cortes
Stephen A. Strickland
Ellen K. Ritchie
Andreas Neubauer
Giovanni Martinelli
Tomoki Naoe
Arnaud Pigneux
Philippe Rousselot
Christoph Röllig
Maria R. Baer
Richard A. Larson
Angela Joubert James
Caroline Chen
Lei Shu
Nahla Hasabou
Erkut Bahceci
Show All
Source
Cite
Save
Citations (9)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.
2016
Journal of Clinical Oncology
Alexander E. Perl
Jorge E. Cortes
Stephen A. Strickland
Ellen K. Ritchie
Andreas Neubauer
Giovanni Martinelli
Tomoki Naoe
Arnaud Pigneux
Philippe Rousselot
Christoph Röllig
Maria R. Baer
Richard A. Larson
Angela Joubert James
Caroline Chen
Lei Shu
Nahla Hasabou
Erkut Bahceci
Show All
Source
Cite
Save
Citations (4)
Statistical Applications in Design and Analysis of In Vitro Safety Screening Assays
2016
Lei Shu
Gary Gintant
Lanju Zhang
Show All
Source
Cite
Save
Citations (0)
1